Lymphoblastoid cell lines (LCLs), which are established by in vitro infection of peripheral B-lymphocytes with Epstein--Barr virus (EBV), are effective antigen-presenting cells. However, the ability of LCLs to present transduced tumor antigens has not yet been evaluated in detail. We report a single-step strategy utilizing a recombinant EBV (maxi-EBV) to convert B-lymphocytes from any individuals into indefinitely growing LCLs expressing a transgene of interest. The strategy was successfully used to establish LCLs expressing Wilms' tumor gene 1 (WT1) tumor antigen (WT1-LCLs), which is an attractive target for cancer immunotherapy. The established WT1-LCLs expressed more abundant WT1 protein than K562 leukemic cells, which are known to overexpress WT1. A WT1-specific cytotoxic T lymphocyte line efficiently lysed the WT1-LCL in a human leukocyte antigenrestricted manner, but poorly lysed control LCL not expressing WT1. These results indicate that the transduced WT1 antigen is processed and presented on the WT1-LCL. This experimental strategy can be applied to establish LCLs expressing other tumor antigens and will find a broad range of applications in the field of cancer immunotherapy.
INTRODUCTION
Epstein--Barr virus (EBV) is a human gammaherpesvirus that can infect primary B-lymphocytes and transform them into continuously growing lymphoblastoid cell lines (LCLs) in vitro. 1 LCLs are valuable tools in immunological studies and can easily be established by infecting peripheral lymphocytes of any individuals with a prototype strain of EBV, B95-8. 2 The majority of cells in the LCLs are latently infected and express a set of EBV latent genes, some of which are responsible for EBV-induced B-cell transformation. 1 In addition, a minority of cells in the LCLs spontaneously enter virus productive cycle and express several lytic genes, although they produce few infectious progeny. As a result, LCLs present immunogenic peptides derived from EBV latent and lytic gene products complexed with major human leukocyte antigen (HLA) molecules on the cell surface. 3, 4 Furthermore, as the process of EBV-induced B-cell immortalization mimics physiological B-cell proliferation, LCLs express various cell surface markers that are preferentially expressed on activated B cells. These markers on LCLs include B-cell activation markers (such as CD23 and CD30), cell-adhesion molecules (such as LFA1, LFA3 and ICAM1) and T-cell costimulatory molecules (such as CD80 and CD86). 5 Owing to the expression of these surface molecules, LCLs, like activated B cells, could serve as good antigen-presenting cells. Antigen presentation of EBV-derived peptides by LCLs is demonstrated by ex vivo expansion of EBV-specific cytotoxic T lymphocytes (CTLs) following co-cultivation of peripheral blood mononuclear cells (PBMCs) with autologous LCLs. 6, 7 Similarly, antigen presentation by EBV-infected B cells also occurs in vivo, leading to the induction of EBV-specific CTL in humans. 8 Such EBV-specific CTL are essential in maintaining control of latently infected cells in vivo, although they are unable to eliminate EBV from the body. 9 Owing to their ease of establishment and cultivation, LCLs are widely used as antigen-presenting cells for a range of foreign antigens. For example, LCLs can be loaded with antigenic peptides, which bind to HLA molecules and are presented on the cell surface. 10 Alternatively, foreign antigens can be expressed in LCLs by infecting LCLs with recombinant retroviruses 11 or adenoviruses expressing foreign antigens. 12 To simplify the establishment of LCLs presenting foreign antigen, a single-step strategy was developed by utilizing so-called 'mini-EBVs'. 13 Mini-EBV (71 kb in size) contains minimal viral genes that are essential for B-cell immortalization, 14, 15 whereas maxi-EBV (175 kb in size) contains an entire EBV genome. 16 In mini-EBV system, a transgene of interest was inserted into a mini-EBV plasmid, and the resultant plasmid was then transfected into a EBV packaging cell line to produce virionpackaged mini-EBV. 13 Infecting B-lymphocytes with virionpackaged mini-EBVs ex vivo results in the establishment of LCLs designated as 'mini-LCLs'. Although this strategy can theoretically be applied to various antigens, it has not been applied to tumorassociated antigens, with the only exception of mini-LCLs expressing Mucin (MUC1). 17 Importantly, HLA-restricted presentation of tumor-associated antigens in mini-LCLs has never been examined to date.
The Wilms' tumor gene 1, WT1, was first identified in a mutated form in the childhood neoplasm, Wilms' tumor, 18 and at that time, wild-type WT1 was categorized as a tumor-suppressor gene. Expression of the WT1 gene is restricted to a limited number of normal tissues including fetal kidney, hematopoietic precursors, ovary, testis and spleen. 19 Later, high levels of WT1 expression in most human acute leukemias 20 and in a variety of malignant solid tumors 21 were reported. The restricted expression of WT1 in normal adult tissues, and its overexpression in a broad spectrum of malignancies, has led to reconsideration of WT1 as a tumorassociated antigen. Thus, WT1 is now recognized as an attractive target for cancer immunotherapy. WT1 peptide-loaded LCLs can efficiently stimulate WT1-specific CTL in vitro and in vivo. 10 We envisioned that expressing whole WT1 protein in LCLs would enable the presentation of multiple WT1 epitopes on the surface of LCLs.
We previously reported that a bacterial artificial chromosome (BAC) clone encompassing the entire EBV (Akata strain) genome can be utilized as a convenient vector for transgene expression in LCLs. 22 We recently established a new BAC clone of B95-8 strain of EBV and improved the method to produce pure recombinant viruses with higher transforming titers. 23 The newly obtained BAC clone (174-kb BAC) is similar to a precedent called 'maxi-EBV', 16 but it is unique in that it stably maintains a viral repetitive sequence (designated as Family of Repeats) and enables production of recombinant EBVs with excellent transgene expression. 23 We applied this novel 'maxi-EBV system' to produce a recombinant EBV expressing WT1. Here, we demonstrate that the recombinant virus enables us to readily establish LCLs expressing WT1, which is processed and presented to HLA-A24-restricted WT1-specific CTLs. The results highlight the utility of this novel maxi-EBV system.
MATERIALS AND METHODS

Cell lines
HEK293 cells 24 and established LCLs were maintained in RPMI 1640 medium (Sigma-Aldrich Fine Chemicals, St Louis, MO) supplemented with 10% fetal bovine serum.
Plasmids
A plasmid double-I-PpoI was constructed as described previously. 22 A kanamycin-resistance gene derived from PUC4K was inserted into the EcoRI site of double-I-PpoI to make double-I-PpoI-km. An mCherry gene or a complementary DNA clone of WT1 (variant D) 25 were cloned into the HincII site of double-I-PpoI to make double-I-PpoI-mCherry or double-IPpoI-WT1, respectively.
Insertion of transgenes into BAC-cloned B95-8-strain EBV genome
Large quantities of BAC clone DNAs were prepared from each 250 ml bacterial culture using a Nucleobond BAC100 kit (Macherey-Nagel, Duren, Germany).
For making EBV-BAC-I-PpoI, a plasmid double-I-PpoI-km (kanamycinresistant gene flanked with two I-PpoI sites) was PCR amplified using a pair of 70-mer oligonucleotides, which carry a 50 nucleotide region homologous to the target region in the 174-kb BAC. A linear PCR product was used as a targeting construct. Recombinogenic engineering of BAC clones was performed in electrocompetent DH10B cells using standard Red/ET protocols. 26 The kanamycin-resistance marker gene was removed by digesting the BAC clone with I-PpoI, followed by selfligation.
EBV-BAC-mCherry and EBV-BAC-WT1 were constructed by inserting the I-PpoI fragment of either double-I-PpoI-mCherry or double-I-PpoI-WT1 into the unique I-PpoI site of EBV-BAC-I-PpoI via in vitro ligation as described. 22 Recombinant virus production HEK293 cells (4 Â 10 5 cells) were plated in six-well tissue culture dishes and transfected with BAC clone DNA (1 mg, prepared with the Nucleobond BAC100 kit) using lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Two days after transfection, the transfected cells were re-plated at a density of 4000 cells per well in 96-well tissue culture plates in medium containing 150 mg of hygromycin per ml. Hygromycin-resistant cell clones with bright green fluorescent protein (GFP) were grown, and clones that were highly competent for entering lytic replication after expressing BZLF1 (a viral switch gene required for progeny virus production) were selected.
HEK293 cells carrying recombinant EBV episomes were transfected with BZLF1 expression vector or with BZLF1 and gp110 expression vectors using lipofectamine 2000. Culture supernatants containing recombinant viruses were harvested at 3 days post-transfection and filtered through 0.45-mm pore-size filter.
B-cell transformation
Blood samples were obtained from normal donors (A24/, A26/33 and A24/11) according to protocols approved by the institutional review board of Aichi Cancer Center, Nagoya, Japan. PBMCs were infected with serially diluted (10 À1 to 10 À3 ) culture supernatants containing recombinant EBV-BAC-WT1 viruses and plated at 1 Â 10 5 cells per well in 96-well tissue culture plates in medium containing cyclosporine A (500 ng ml --1 ). Half of the culture medium was replaced with fresh medium containing cyclosporine A every 5 days. The established LCLs were expanded in culture medium containing hygromycin (50 mg ml --1 ). For checking GFP and mCherry expression, cells were fixed in phosphate-buffered saline (without calcium and magnesium) containing 0.5% paraformaldehyde. Fluorescence was measured using a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA). The green (GFP) and red (mCherry) emissions from each cell line were measured using FL1 and FL2 channels, respectively, without color compensation. Data analysis was done using CellQuest software (Becton Dickinson).
Western blot analysis
Whole cell extracts were prepared by lysing cells with sodium dodecyl sulfate lysis buffer (3% sodium dodecyl sulfate, 10% glycerol, 125 mM Tris-Cl pH 6.7, 6% urea) at a concentration of 1 Â 10 7 per ml. Aliquots of whole cell extracts were analyzed by sodium dodecyl sulfate-7% polyacrylamide gel electrophoresis. Western blot analysis was performed according to standard ECL protocols. Anti-WT1 rabbit polyclonal antibody (1:500 dilution; C19, Santa Cruz, Santa Cruz, CA, USA) was used as a primary antibody, and a horseradish peroxidase-conjugated anti-rabbit immunoglobulin G (1:2000; GE Healthcare, Piscataway, NJ, USA) was used as a secondary antibody.
Cytotoxicity assays
Cytotoxic assays were performed as described previously. 27 Briefly, 1 Â 10
Cr (Na 2 51 CrO 4 )-labeled target cells in 100 ml RPMI 1640 medium supplemented with 10% fetal bovine serum (assay medium) were seeded into a 96-well round-bottom microtiter plate and incubated with and without a synthetic 9-mer peptide CMTWNQMNL (residues 235--243) for 2 h. A T-cell line retrovirally transduced with HLA-A24-restricted WT1-specific T cell receptor (TCR) a/b genes (WT1-TCR-CTL) 28 was used as effector cells in the assays. Varying numbers of WT1-TCR-CTL suspended in 100 ml assay medium were added to the well, and the plate was incubated at 37 1C for 4 h. After the incubation, 100 ml supernatant was collected from each well, and its radioactivity was counted on a g-scintillation counter. 
RESULTS
Production of recombinant EBVs with various transgenes
We recently obtained a novel EBV(B95-8 strain)-BAC clone, designated as the 174-kb BAC. 23 The 174-kb BAC contained a GFP transgene driven by the CAG promoter (a chimeric promoter consisting of cytomegalovirus-immediate early, chicken b-actin, and rabbit b-globin promoters) (Figure 1 ), which works efficiently in a broad spectrum of cells. 29 The 174-kb BAC clone DNA was stably transfected into HEK293 cells to obtain virus-producing cells, and recombinant EBV derived from the 174-kb BAC exhibited high B-cell transformation efficiency. PBMC from healthy donors were infected with the recombinant EBV of the 174-kb BAC. GFP expression in the transformed lymphocytes became apparent starting at 3 days post-infection. Multiple lines of LCL were established within 1 month after infection, and were cultured with hygromycin selection to minimize the loss of EBV episomes. In most LCL cultures, 490% of the cells were GFP-positive (Figure 2 ). Thus, a recombinant EBV derived from the 174-kb BAC appeared to be useful for expressing transgenes in LCLs derived from a range of different individuals.
We set out to modify the 174-kb BAC clone so that we could easily replace the GFP with other transgenes. We introduced a recognition sequence of an intron-encoded endonuclease I-PpoI into the 174-kb BAC (Figure 1 ). The recognition sequence of I-PpoI is longer than 15 bp 30 and is absent from the parental 174-kb BAC. Thus, the artificially created I-PpoI site is a unique site within the modified BAC clone, and enables the insertion of complementary DNA cassettes by simple in vitro ligation. 22 As a proof of concept, we used the strategy to generate a recombinant EBV genome with a red fluorescent protein (mCherry) transgene. 31 An mCherry gene was inserted into the created I-PpoI site to obtain EBV-BAC-mCherry (Figure 1 ). The recombinant EBV expressing mCherry was produced using a similar protocol to that used for producing the 174-kb BAC virus, and peripheral B-lymphocytes were infected with the recombinant virus expressing the mCherry transgene. Multiple lines of LCL expressing mCherry were established (mCherry-LCLs), with most cultures containing 490% mCherry-positive cells (Figure 2 ). These results indicate that it should be feasible to establish LCLs expressing any kind of antigen, unless the antigen impairs the growth of LCLs.
Establishing LCLs expressing WT1 antigen
We then proceeded to apply the strategy to establish LCLs expressing the WT1 tumor antigen. A WT1 complementary DNA (variant D) 25 was inserted into the unique I-PpoI site of the parental BAC clone to construct EBV-BAC-WT1, and virus-producing cells were obtained by stable transfection of the EBV-BAC-WT1 into HEK293 cells.
PBMC from three healthy donors (donor 1, HLA A24/; donor 2, HLA A26/33; and donor 3, A24/11) were infected with the recombinant EBV derived from EBV-BAC-WT1 to establish LCLs expressing WT1 (WT1-LCLs). PBMCs from the same donors were also infected with the parental 174-kb BAC virus to establish GFP-LCLs. Multiple WT1-LCLs and GFP-LCLs were obtained from the lymphocytes of three donors. The expression of WT1 in the WT1-LCLs was examined by western analysis, along with a human leukemic cell line K562 as a positive control for WT1 expression. A representative result obtained using cell extracts from two independent lines of GFP-LCL and WT-LCL (both derived from donor 1) is shown in Figure 3a . WT1-LCLs expressed substantial amounts of the protein, whereas GFP-LCLs did not express any detectable WT1 protein. The expression of WT1 in the WT1-LCLs was significantly higher than in K562 cells (Figure 3a) . WT1-LCLs derived from the donor 2 and 3 also expressed substantial amounts of WT1 (Figure 3b ), clearly demonstrating that this experimental strategy can be applied to any individual.
We utilized immunofluorescence to measure the frequency of WT1-positive cells in the WT1-LCLs. The majority of WT1-LCL cells expressed WT1 (Figure 3c ), although the staining intensity was heterogeneous among the cells. Such heterogeneity is characteristic of transgene expression from episomally maintained EBV genomes, as varied copies of episomes are maintained in individual cells. A higher magnification image obtained by a confocal microscopy revealed that WT1 localized in the nuclei of the WT1-LCLs and constituted several densely stained nuclear dots (Figure 3d ).
WT1 antigen presentation in WT1-LCLs Although WT1 is a nuclear protein, it is processed and presented as a short peptide to relevant CTLs. 32 We examined whether WT1 was processed and presented on the WT1-LCLs as evidenced by specific lysis by WT1-specific CTLs. To this end, we utilized a T-cell line expressing HLA-A24-restricted WT1-specific TCR a/b chains (WT1-TCR-CTL) 28 as effector cells in CTL assays. A set of WT1-LCL(A24/) and GFP-LCL(A24/), both derived from the donor 1 lymphocytes, were used as target cells in CTL assays, in the presence or absence of WT1-specific peptide pulsing. When LCLs were pulsed with the peptide, both the WT1-LCL(A24/) and the GFP-LCL(A24/) were efficiently lysed by the WT1-TCR-CTL (Figure 3a ). In the absence of the peptide, the GFP-LCL(A24/) was poorly lysed by the WT1-TCR-CTL. By contrast, the WT1-LCL (A24/) was efficiently lysed by WT1-TCR-CTL (440% specific lysis at effector: target ratio of 5:1) (Figure 4 ). We then examined whether the observed killing by WT1-TCR-CTL was HLA-A24 restricted. For this purpose, a set of WT1-LCL(A26/33) and a GFP-LCL(A26/33), both derived from the donor 2 lymphocytes, were used in the CTL assay. Both WT1-LCL(A26/33) and the control LCL(A26/33) were not lysed by WT1-TCR-CTL, regardless of WT1-peptide pulsing. These results indicate that the WT1-derived peptide was presented on the WT1-LCL in an HLA-restricted manner. Therefore, we conclude that the WT1-LCLs serve as target cells of WT1-specific CTLs, and that our experimental strategy provides useful research tools in the field of cancer immunotherapy. DISCUSSION EBV-LCLs are regarded as convenient tools for a variety of immunological studies, as they can be easily established from peripheral blood of any individual, and it is relatively easy to obtain large quantities without the aid of exogenous cytokines. We demonstrated here that a novel 'maxi-EBV' with a WT1 transgene can be used to readily convert resting B-lymphocytes to WT1-expressing LCLs ex vivo.
A strategy to establish LCLs with transgene expression requires two successive procedures: first, establishing LCLs using the B95-8 strain of EBV and, second, transducing the established LCLs by plasmid transfection or recombinant virus infection (either retrovirus or adenovirus). 11, 12 A previously reported mini-EBV system is an attractive alternative, as one can convert PBMC to transgeneexpressing LCLs via just single infection of mini-EBV. 13 On the other hand, production of mini-EBVs requires EBV packaging cell lines, and, as a result, recombinational events between mini-EBVs and helper virus genomes can be problematic. The advantage of maxi-EBV system is its simplicity; once HEK293 cells harboring maxi-EBVs are established, maxi-EBVs are stably maintained in the cells and can repeatedly produce viruses. A maxi-EBV lacking viral transactivator BZLF1, a critical switch gene for progeny virus production, was previously reported, 33 and similar modification is expected to solve the safety issue of our maxi-EBV system in the future.
We, for the first time, quantitatively evaluated the expression level of various transgenes in the established LCLs. Fluorescenceactivated cell sorting, immunofluorescence and western analyses demonstrated the excellent levels of transgene expression. Latently infected maxi-EBV are maintained as episomes and do not integrate into host chromosomes. Therefore, the WT1 transgene is essentially free from position effects associated with chromosomal integration. 34 As a result, high-level expression of WT1 protein can be maintained during proliferation of WT1-LCLs.
This strategy is applicable for individuals with any HLA type. Our data clearly indicate that WT1 is processed and presented as an HLA-binding peptide on WT1-LCLs. Although we examined only one HLA class I-associated epitope, it is highly likely that others, including epitopes complexed with HLA class II, are also presented on WT1-LCLs. In addition, the strategy can be applied for any other tumor antigens, unless they impair the growth of LCLs. LCLs expressing tumor antigens can be ideal target cells of tumor antigen-specific CTLs.
On the other hand, using WT1-LCLs for ex vivo CTL induction can be problematic. Our attempts to utilize WT1-LCLs for ex vivo expansion of WT1-specific CTL were hampered by several technical limitations. For example, as the blood donors were EBVseropositive and their PBMC contained pre-existing EBV-specific memory T cells, the expansion of EBV-specific CTLs became predominant after co-cultivation with autologous WT1-LCLs. We also tested a WT1-LCL derived from EBV-seronegative donor (donor 3, see Figure 3b ) for ex vivo WT1-specific CTL induction, expecting that the lack of EBV-specific memory T cells favor the induction of WT1-specific CTLs. However, induction of WT1-specific CTL again failed (data not shown). Clearly, we need to test alternative experimental strategies. One possibility is to utilize WT1 peptide-pulsed dendritic cells for initial priming before the co-cultivation with WT1-LCLs. Another possibility is to utilize truncated WT1 protein instead of the full-length WT1 for transgene expression. This may augment immunogenicity because previous studies demonstrated that human WT1 truncated at the carboxy-terminal end localizes to the cytoplasm and is more immunogenic than its full-length counterpart. 35, 36 In summary, we developed a novel maxi-EBV strategy to establish LCLs potentially capable of expressing various tumor antigens as transgenes. These LCLs expressing tumor antigens can be used as target cells in CTL assay, providing useful research tools in the field of cancer immunotherapy. The utility of these LCLs for ex vivo CTL expansion is currently unclear, and should be pursued in the future. , were used as targets in a cytotoxicity assay. Where indicated, cells were loaded with WT1-derived peptide (CMTWNQMNL). Note that WT1-LCL(A24/) was specifically lysed by WT1-TCR-CTL, whereas GFP-LCL(A24/) was barely lysed by the same CTL.
